- Daiichi Sankyo posts 'extraordinary loss' of nearly $1BDaiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising deman…Endpoints · 2mo ago↗ source
- FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...Endpoints · 2mo ago↗ source
- 'Pharma, not really’: Top young AI talent shuns careers at big drugmakersRIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medica…